CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	[1]
Current assets:
Cash and cash equivalents	$ 479,193	$ 278,096
Short-term marketable securities	0	72,749
Related party receivables from collaborative arrangements	92,150	79,427
Prepaid expenses and other current assets	698	962
Total current assets	572,041	431,234
Property and equipment, net	33	33
Equity investments	111,745	0
Capitalized fees paid to a related party, net	128,708	139,076
Deferred tax assets, net	109,490	154,171
Other assets	239	312
Total assets	922,256	724,826
Current liabilities:
Accounts payable	623	10
Accrued personnel-related expenses	384	647
Accrued interest payable	1,668	4,152
Other accrued liabilities	1,223	562
Total current liabilities	3,898	5,371
Long-term debt, net of discount and issuance costs	383,350	377,120
Other long-term liabilities	136	219
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding	0	0
Common stock: $0.01 par value, 200,000 shares authorized, 101,392 and 101,288 issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	1,014	1,013
Additional paid-in capital	1,260,447	1,258,859
Accumulated other comprehensive income	0	27
Accumulated deficit	(775,905)	(946,404)
Total Innoviva stockholders' equity	485,556	313,495
Noncontrolling interest	49,316	28,621
Total stockholders' equity	534,872	342,116
Total liabilities and stockholders' equity	$ 922,256	$ 724,826

[1] Consolidated balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements.